Related Experiment Videos
Miglitol, a new alpha-glucosidase inhibitor
J P Sels1, M S Huijberts, B H Wolffenbuttel
1Department of Endocrinology, University Hospital Maastricht, PO Box 5800, 6202 AZ Maastricht, The Netherlands. jse@sint.azm.nl
Expert Opinion on Pharmacotherapy
|March 16, 2001
Summary
Miglitol, an alpha-glucosidase inhibitor, effectively reduces post-meal blood glucose spikes in type 2 diabetes. It offers an insulin-sparing effect, potentially aiding weight management and reducing hypoglycemia risk.
Area of Science:
- Pharmacology
- Endocrinology
- Metabolic Diseases
Background:
- Miglitol is a second-generation alpha-glucosidase inhibitor derived from 1-desoxynojirimycin.
- It reversibly inhibits brushborder alpha-glucosidase enzymes, impacting carbohydrate digestion.
Purpose of the Study:
- To evaluate the efficacy and safety of miglitol in managing blood glucose levels.
- To compare miglitol's effects with other antidiabetic agents, particularly sulfonylureas.
Main Methods:
- Administration of miglitol with main meals to blunt postprandial glucose increase.
- Assessment of effects on fasting blood glucose, HbA1c, serum insulin levels, and body weight.
Main Results:
- Miglitol blunts postprandial blood glucose increase with minimal effect on fasting glucose.
- Achieves moderate HbA1c reduction (0.3-0.7%) in Type 2 diabetes.
- Demonstrates an insulin-sparing effect, potentially reducing weight gain and hypoglycemia risk compared to sulfonylureas.
Conclusions:
- Miglitol is effective in managing postprandial hyperglycemia in Type 2 diabetes.
- Its insulin-sparing profile offers potential advantages over sulfonylureas regarding weight and hypoglycemia.
- Further long-term studies are needed for Type 1 diabetes and comprehensive clinical assessment.